NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although the negative prognostic role of pre-HSCT MRD is established, no recommendations are available for the management of peri-transplant molecular failure (MF). Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine (AZA) as bridge-to-transplant strategy in 11 NPM1mut MRD-positive fit AML patients. Patients were in MRD-positive complete remission (CRMRDpos) at the time of treatment: nine in molecular relapse and two in molecular persistence. After a median number of two cycles (range 1–4) of VEN–AZA, 9/11 (81.8%) achieved CRMRD-negative (CRMRDneg). All 11 patients proceeded to HSCT. With a median follow-up from treatment start of 26 months, and a median post-HSCT follow-up of 19 months, 10/11 patients are alive (1 died from non-relapse mortality), and 9/10 patients are in MRDneg status. This patient series highlights the efficacy and safety of VEN–AZA to prevent overt relapse, achieve deep responses and preserve patient fitness before HSCT, in patients with NPM1mut AML in MF.

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure / Sartor C.; Brunetti L.; Audisio E.; Cignetti A.; Zannoni L.; Cristiano G.; Nanni J.; Ciruolo R.; Zingarelli F.; Ottaviani E.; Patuelli A.; Bandini L.; Forte D.; Sciabolacci S.; Cardinali V.; Papayannidis C.; Cavo M.; Martelli M.P.; Curti A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 202:3(2023), pp. 599-607. [10.1111/bjh.18887]

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure

Sartor C.;Zannoni L.;Cristiano G.;Nanni J.;Ciruolo R.;Zingarelli F.;Ottaviani E.;Patuelli A.;Bandini L.;Forte D.;Papayannidis C.;Cavo M.;
2023

Abstract

NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although the negative prognostic role of pre-HSCT MRD is established, no recommendations are available for the management of peri-transplant molecular failure (MF). Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine (AZA) as bridge-to-transplant strategy in 11 NPM1mut MRD-positive fit AML patients. Patients were in MRD-positive complete remission (CRMRDpos) at the time of treatment: nine in molecular relapse and two in molecular persistence. After a median number of two cycles (range 1–4) of VEN–AZA, 9/11 (81.8%) achieved CRMRD-negative (CRMRDneg). All 11 patients proceeded to HSCT. With a median follow-up from treatment start of 26 months, and a median post-HSCT follow-up of 19 months, 10/11 patients are alive (1 died from non-relapse mortality), and 9/10 patients are in MRDneg status. This patient series highlights the efficacy and safety of VEN–AZA to prevent overt relapse, achieve deep responses and preserve patient fitness before HSCT, in patients with NPM1mut AML in MF.
2023
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure / Sartor C.; Brunetti L.; Audisio E.; Cignetti A.; Zannoni L.; Cristiano G.; Nanni J.; Ciruolo R.; Zingarelli F.; Ottaviani E.; Patuelli A.; Bandini L.; Forte D.; Sciabolacci S.; Cardinali V.; Papayannidis C.; Cavo M.; Martelli M.P.; Curti A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 202:3(2023), pp. 599-607. [10.1111/bjh.18887]
Sartor C.; Brunetti L.; Audisio E.; Cignetti A.; Zannoni L.; Cristiano G.; Nanni J.; Ciruolo R.; Zingarelli F.; Ottaviani E.; Patuelli A.; Bandini L.; Forte D.; Sciabolacci S.; Cardinali V.; Papayannidis C.; Cavo M.; Martelli M.P.; Curti A.
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2023 - Sartor - A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐mutated acute myeloid.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 892.66 kB
Formato Adobe PDF
892.66 kB Adobe PDF Visualizza/Apri
bjh18887-sup-0001-figures1-s2.docx

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 76.14 kB
Formato Microsoft Word XML
76.14 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/959171
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact